Understanding the specific details of the mechanisms of YAP/TAZ activation and suppression and their transcription promotion in epidermal KCs would support drug development for hyperproliferative epidermal diseases and anti-cancer therapy, as well as for maintaining KC proliferation and stimulating wound healing in epidermolysis bullosa or chronic ischemic wounds due to diabetes. The gene discussed is YAP1; the disease is keratoconus.